Jane Street Group LLC Has $493,000 Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Jane Street Group LLC trimmed its position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 63.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,344 shares of the biopharmaceutical company's stock after selling 92,231 shares during the quarter. Jane Street Group LLC owned approximately 0.11% of Theravance Biopharma worth $493,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its holdings in Theravance Biopharma by 21.1% during the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company's stock valued at $181,000 after purchasing an additional 3,349 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Theravance Biopharma by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after purchasing an additional 2,060 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma in the 4th quarter valued at $103,000. Magnetar Financial LLC increased its position in shares of Theravance Biopharma by 125.8% in the 4th quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock valued at $259,000 after buying an additional 15,328 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Theravance Biopharma by 11.9% in the 4th quarter. American Century Companies Inc. now owns 77,931 shares of the biopharmaceutical company's stock valued at $733,000 after buying an additional 8,289 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on TBPH shares. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $11.33.

Theravance Biopharma Price Performance

TBPH traded down $0.05 during trading on Friday, reaching $9.25. The company had a trading volume of 200,660 shares, compared to its average volume of 268,747. Theravance Biopharma, Inc. has a 12 month low of $7.44 and a 12 month high of $10.90. The business's fifty day moving average price is $9.16 and its 200 day moving average price is $9.35. The company has a market cap of $462.51 million, a P/E ratio of -9.16 and a beta of -0.10.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $15.39 million during the quarter, compared to the consensus estimate of $28.08 million. As a group, sell-side analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 370,038 shares in the company, valued at approximately $3,330,342. The trade was a 1.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 6.90% of the company's stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.